Abivax Shares Rocket Amid Rumors of Eli Lilly's Billion-Euro Buyout Interest

Monday saw Abivax (EPA: ABVX) climbing by more than 23% on the Paris exchange, fueled by fresh rumors that U.S. pharmaceutical giant Eli Lilly (NYSE: LLY) remains keen on snapping up the French biotech firm. Shares even flirted with an all-time high, flirting around €130 before settling slightly lower at €121.60.

The buzz began when French media outlet La Lettre disclosed that Eli Lilly might be preparing an offer nearing €15 billion - roughly double Abivax's current market cap. No formal bid has landed on Abivax's board yet, but whispers suggest Eli Lilly is just waiting on approval from French foreign investment authorities before making a move.

Meanwhile, Abivax's CEO Marc de Garidel stayed focused on the company's core mission during the JPMorgan Healthcare Conference in San Francisco. He highlighted their lead drug candidate, obefazimod, as a game changer in ulcerative colitis treatment, potentially becoming one of the next decade's blockbuster therapies. Despite the takeover chatter, he brushed off rumors as outside noise, signaling Abivax's attention remains on progressing clinical development.

Wall Street analysts are chiming in as well. Kepler Cheuvreux's Justine Telliez outlined that Abivax now stands out as a prime M&A target in the inflammatory bowel disease space, especially after delivering promising Phase III data on ulcerative colitis. Her valuation range for a potential buyout spans €150 to €250 per share - well above their €130 standalone target price - reflecting typical acquisition premiums for control and possible synergies.

Of course, the final deal price hinges on factors like who emerges as the frontrunner, any lingering doubts over the drug's long-term durability, and the intensity of bidding competition. Eli Lilly's appetite here is no secret, but whether they'll come in hot enough to seal the deal remains uncertain.

The story adds a fresh twist to biotech M&A dynamics this year, spotlighting how a relatively small-cap player can spark giant pharma's interest. Back in the pharma trenches, big companies are always on the lookout for pipeline gems to sustain growth amid patent cliffs and competitive pressures.

What makes obefazimod intriguing to pharma giants is its oral administration route targeting ulcerative colitis, a chronic inflammatory condition with significant unmet needs. If Abivax nails regulatory approval, that could redefine treatment standards and create new revenue streams.

As of now, Abivax's share price is dancing to the tune of takeover speculation. Will Eli Lilly play their hand or watch and wait? The next few weeks could provide some clarity. Meanwhile, traders are snapping up shares with the fervor typical when a smaller biotech grabs the spotlight for all the right reasons-or rumors thereof.